SCHEMBL14936723

SCHEMBL14936723

CN(c1cc(O)cc(N2CCN(CCO)CC2)c1)c1nc2ccc(-c3cc(O)ccc3Cl)cn2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 4/20 0.39
ENPP2 Q13822 2/20 0.36
DRD2 P14416 3/20 0.35
DRD4 P21917 3/20 0.35
DRD3 P35462 3/20 0.35
SUV39H2 Q9H5I1 3/20 0.35
HTR1A P08908 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
HTR7 P34969 4/20 0.33
BCL2A1 Q16548 1/20 0.32
DYRK3 O43781 1/20 0.31
CCNT1 O60563 1/20 0.31
CDK9 P50750 1/20 0.31
DYRK1A Q13627 1/20 0.31
DYRK2 Q92630 1/20 0.31
DYRK1B Q9Y463 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14936950 0.83 PIK3CG (0.36) SRC
SCHEMBL14936291 0.81 SRC (0.43) SRCESR1ESR2HTR7
SCHEMBL14936919 0.78 PIK3CG (0.40) SRC
SCHEMBL42448 0.77 SRC (0.48) SRC
SCHEMBL41600 0.75 SRC (0.44) SRCDRD2DRD4DRD3HTR1A
SCHEMBL14937276 0.75 PIK3CG (0.34) SRCESR1ESR2
SCHEMBL14936009 0.74 PIK3CG (0.35) SRC
SCHEMBL14937044 0.74 PIK3CG (0.33) SRC
SCHEMBL41486 0.72 SRC (0.65) SRCHTR1AADRA1ADYRK3
SCHEMBL41603 0.71 SRC (0.63) SRCDYRK3CCNT1CDK9DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION CAMK2D, CAMK2A, CAMK2B SRC 401/4885ENPP2 747/4885DRD2 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.